Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast Report Coverage

Expert Market Research's “Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of exocrine pancreatic insufficiency (EPI). It projects the future incidence and prevalence rates of exocrine pancreatic insufficiency (EPI) cases across various populations. The study covers age, gender, and type as major determinants of the exocrine pancreatic insufficiency (EPI) population. The report highlights patterns in the prevalence of exocrine pancreatic insufficiency (EPI) over time and projects future trends based on multiple variables.

Exocrine Pancreatic Insufficiency (EPI) Understanding: Disease Overview

Exocrine pancreatic insufficiency (EPI) occurs when the pancreas fails to produce sufficient digestive enzymes, resulting in impaired nutrient absorption. It commonly arises from chronic pancreatitis, cystic fibrosis, pancreatic cancer, pancreatic surgery, and sometimes long-standing diabetes. EPI leads to steatorrhea, weight loss, vitamin deficiencies, bloating, and malnutrition. Disease progression varies depending on underlying etiology, with chronic inflammatory and fibrotic pancreatic changes being major contributors. Early diagnosis is essential, yet EPI remains underrecognized, particularly in mild or slowly progressive cases, leading to significant nutritional and metabolic complications.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology Perspective

The exocrine pancreatic insufficiency (EPI) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for exocrine pancreatic insufficiency (EPI) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for exocrine pancreatic insufficiency (EPI) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Exocrine pancreatic insufficiency is most commonly associated with chronic pancreatitis, where 60% to 90% of patients develop EPI within a decade of diagnosis.
• Episodes of acute pancreatitis significantly increase the risk of EPI, with prevalence reaching 62% during hospitalization and stabilizing near 35% during follow-up. Severe or recurrent acute pancreatitis, pancreatic necrosis, diabetes, and alcohol-related disease substantially increase long-term EPI risk.
• In cystic fibrosis (CF), EPI follows a very different and far more immediate trajectory. Due to genetically driven obstruction of pancreatic ducts, 80–90% of people with CF develop EPI, many within the first months of life.
• Diabetes contributes to a notable secondary burden of EPI. Approximately 10-30% of individuals with type 1 diabetes and 5-46% of those with type 2 diabetes show varying degrees of EPI, although most cases are mild to moderate. In type 2 diabetes, meta-analytic evidence shows that about 22% of patients have measurable exocrine insufficiency, with severe EPI occurring in around 8%. Prevalence varies across regions, reaching as high as 35% in some Asian populations.
• EPI prevalence is extremely high among patients with advanced pancreatic cancer (66-92%) due to profound exocrine tissue loss. Additionally, 14-74% of individuals with inflammatory bowel disease may develop EPI. Bariatric surgery patients and individuals with HIV infection also show elevated prevalence, estimated at 26-45%, highlighting the diverse etiologic pathways contributing to global EPI incidence.

Read more about this report - Request a Free Sample

Country-wise Exocrine Pancreatic Insufficiency (EPI) Epidemiology

The exocrine pancreatic insufficiency (EPI) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The United States continues to observe a rising clinical awareness of exocrine pancreatic insufficiency, particularly due to its strong association with chronic pancreatitis. Current estimates show that chronic pancreatitis affects 42 to 73 individuals per 100,000, positioning it as the leading pancreatic disorder contributing to EPI development nationwide. As diagnostic tools improve and recognition expands across healthcare settings, understanding the evolving epidemiological landscape remains essential for strengthening patient management and informing future therapeutic priorities in the United States.

Exocrine Pancreatic Insufficiency (EPI): Treatment Overview

Treatment for exocrine pancreatic insufficiency focuses on replacing missing digestive enzymes and correcting nutritional deficits. Pancreatic enzyme replacement therapy (PERT) is the standard, delivering lipase, amylase, and protease to improve fat and nutrient absorption. Therapy is often combined with dietary modifications, fat-soluble vitamin supplementation, and management of underlying causes such as chronic pancreatitis or cystic fibrosis. Optimizing dosage, timing with meals, and adherence significantly improves symptoms and quality of life. Adjunctive therapies, including proton-pump inhibitors, may enhance enzyme activity in select patients. Long-term follow-up ensures nutritional stability.

Key Questions Answered

• What are the key findings of exocrine pancreatic insufficiency (EPI) epidemiology in the 8 major markets?
• What will be the total number of patients with exocrine pancreatic insufficiency (EPI) across the 8 major markets during the forecast period?
• What was the country-wise exocrine pancreatic insufficiency (EPI) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of exocrine pancreatic insufficiency (EPI) patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of exocrine pancreatic insufficiency (EPI) during the forecast period of 2026-2035?
• What are the currently available treatments for exocrine pancreatic insufficiency (EPI)?
• What are the disease risks, signs, symptoms, and unmet needs of exocrine pancreatic insufficiency (EPI)?

Scope of the Exocrine Pancreatic Insufficiency (EPI) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of exocrine pancreatic insufficiency (EPI) based on several factors.
• Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The exocrine pancreatic insufficiency (EPI) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Exocrine Pancreatic Insufficiency Treatment Market

Pancreatic Neuroendocrine Tumors Pipeline Analysis